Skip to main content
. 2024 Nov 25;15:10213. doi: 10.1038/s41467-024-53223-3

Fig. 4. Probability of PFS according to baseline HER2 biomarker status.

Fig. 4

The probability of PFS is shown according to HER2 IHC status (panel A) HER2 biomarkers based on exploratory cutoff values (panels B, C, D, F, G), and type of HER2 gene amplification (panel E). aExploratory cutoff values (panels B, C, D, F, G) were determined using receiver operating characteristics analysis: H-score cutoff = 240; HER2/CEP17 ratio cutoff = 6.30; HER2 ISH signal cutoff = 11.25; HER2 ApCN cutoff = 30.99; serum HER2ECD cutoff = 23.5 ng/mL. bAmplification type (panel E) was reported from Guardant Health. Amp, amplification; ApCN, adjusted plasma copy number; HER2, human epidermal growth factor receptor 2; HER2ECD, human epidermal growth factor receptor 2 extracellular domain; IHC, immunohistochemistry; ISH, in situ hybridization; mPFS, median progression-free survival; NA, not applicable; ND, not determined; PFS, progression-free survival.